[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525767":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":31,"collaborators":7,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":7,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":7,"enrollmentInfo":42,"targetDuration":7,"studyType":45,"phases":7,"briefSummary":46,"conditions":47,"keywords":7,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"Boryung Pharmaceutical Co., Ltd","INDUSTRY",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Shinyoung Oh","CONTACT","+82-2-708-8000","syoh@boryung.co.kr",[15],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":21,"countryCode":7,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"DongGuk university Ilsan hospital","RECRUITING","Goyang-si","Gyeonggi-do","10326","South Korea",{"type":23,"coordinates":24},"Point",[25,26],126.835,37.65639,{"lat":26,"lon":25},[29],{"name":30,"role":11,"phone":7,"phoneExt":7,"email":7},"Jangwook Lee",{"type":32,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100525767","a-observational-study-to-evaluate-the-efficacy-and-safety-of-pacitol-inj-100525767",false,"NCT06126016","A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.","A Multi-center, Prospective, Non-interventional, Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.(Paricalcitol) for Secondary Hyperparathyroidism With Stage 5D Chronic Kidney Disease (CKD 5D) Receiving Hemodialysis","Inclusion Criteria:\n\n* Among hemodialysis patients with secondary hyperparathyroidism due to chronic kidney disease (CKD 5D), those who are scheduled to administer Pacitol Inj. according to the product information.\n* Those who voluntarily signed a written personal information collection and usage agreement to participate in this clinical study after receiving an explanation about the objective and methods of the study.\n* Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.\n\nExclusion Criteria:\n\n* Those with a history of hypersensitivity reactions to this drug or its components\n* Those with evidence of vitamin D toxicity\n* Those with hypercalcemia at enrollment\n* Pregnant or lactating women\n* Those with evidence of parathyroid adenoma who is scheduled to undergo parathyroidectomy.\n* Those who have been administered with investigational drugs of other clinical trials within 12 weeks from the baseline(Visit 1).\n* Those who are judged by the principle Investigator or sub-Investigator to be ineligible to participate in the study.","ALL","19 Years",{"count":43,"type":44},1000,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate the efficacy and safety of pacitol Inj.(paricalcitol) for secondary hyperparathyroidism with stage 5D chronic kidney disease (CKD 5D) receiving hemodialysis",[48,49],"Chronic Kidney Disease 5D","Secondary Hyperparathyroidism","2024-12-10",{"date":52,"type":53},"2024-12-12","ACTUAL",{"date":55,"type":53},"2023-10-19",{"date":57,"type":44},"2026-04",{"name":5,"class":6},1]